Fig. 7

Immunohistochemical staining and immunofluorescence of FBN1, p‐VEGFR2, and p‐STAT2. (A) Representative images of immunohistochemistry of FBN1, p‐VEGFR2 (Tyr1054), and p‐STAT2 (Tyr690) in ovarian cancer tissues. (B) Human serum VEGFA concentration in 50 pairs of ovarian cancer patients measured by ELISA kit. (C‐D) Association between SUVmax of PET/CT technology and FBN1 expression in the lesions of adnexal carcinomas from 100 ovarian cancer patients. (E) The relationship between SUVmax of PET/CT image and overall survival of 100 ovarian cancer patients. (F) mRNA expression levels of genes associated with glycolysis and angiogenesis assessed via qRT‐PCR in 45 pairs of ovarian cancer samples with high or low FBN1 expression. (G) Representative images of immunofluorescence of FBN1, p‐VEGFR2 (Tyr1054), and p‐STAT2 (Tyr641) in ovarian cancer patients’ tissues. Green signals, FBN1 or p‐VEGFR2 (Tyr1054); red signals, p‐VEGFR2 (Tyr1054) or p‐STAT2 (Tyr641); blue signals, DAPI. (H) Schematic model on the proposed role of the FBN1/VEGFR2/STAT2 signaling axis in modulating glycolysis, angiogenesis, and cisplatin sensitivity. Abbreviations: FBN1, fibrillin‐1; ELISA, enzyme‐linked immunosorbent assay; SUVmax, maximum of standardized uptake value; PET‐CT, positron emission tomography‐computed tomography; VEGFA, vascular endothelial growth factor A; STAT2, signal transducer and activator of transcription 2; VEGFR2, vascular endothelial growth factor receptor 2; DAPI, 2‐(4‐amidinophenyl)‐6‐indolecarbamidine dihydrochloride